Loading the security overview…
Where the tokens are
Peers
5 of 14 have tokenized versionsFirst the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside NTRA. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
 NTRAThis companyNatera, Inc. Common Stock | — | $58.88B | — | 21.8 | -256.5 | −10.6% | 3/9 | safe |
 BLLNBillionToOne, Inc. Class A Common Stock | Cancer Diagnostics & BiomarkersGenetic Testing & Diagnostics | $4.99B | 166.0 | 12.6 | 93.4 | 5.6% | — | safe |
 VCYTVeracyte, Inc. | Cancer Diagnostics & BiomarkersGenetic Testing & Diagnostics | $3.55B | 31.0 | 6.3 | 25.7 | 8.3% | 7/9 | safe |
 NEONeoGenomics, Inc. | Cancer Diagnostics & BiomarkersGenetic Testing & Diagnostics | $2.28B | — | 3.0 | 532.8 | −6.6% | 4/9 | safe |
 PSNLTokenizedPersonalis, Inc. Common Stock | Cancer Diagnostics & BiomarkersGenetic Testing & Diagnostics | $1.73B | — | 24.8 | -15.6 | −45.6% | 2/9 | safe |
 ILMNTokenizedIllumina Inc | Genetic Testing & Diagnostics | $40.12B | 48.6 | 8.9 | 36.5 | 29.1% | 7/9 | safe |
 LHLabcorp Holdings Inc. | Genetic Testing & Diagnostics | $24.7B | 24.6 | 1.7 | 13.1 | 11.7% | 8/9 | safe |
 GHTokenizedGuardant Health, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $23.45B | — | 19.8 | -55.4 | 203.5% | 3/9 | safe |
 TXG10x Genomics, Inc. Class A Common Stock | Genetic Testing & Diagnostics | $11.56B | — | 18.8 | -213.6 | −9.1% | 3/9 | safe |
 QGENQIAGEN N.V. | Genetic Testing & Diagnostics | $9.06B | — | — | — | — | 7/9 | safe |
 CAITokenizedCaris Life Sciences, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $8.01B | 76.2 | 8.1 | 44.3 | 17.8% | 5/9 | safe |
 GRALGRAIL, Inc. Common Stock | Cancer Diagnostics & Biomarkers | $5.92B | — | 35.8 | -15.5 | −15.4% | 4/9 | safe |
 ADPTAdaptive Biotechnologies Corporation Common Stock | Cancer Diagnostics & Biomarkers | $4.37B | — | 14.2 | -212.6 | −44.7% | 5/9 | safe |
 CDNACareDx, Inc. | Genetic Testing & Diagnostics | $3.43B | 30.9 | 7.5 | 300.0 | 26.1% | 5/9 | safe |
 WGSTokenizedGeneDx Holdings Corp. Class A Common Stock | Genetic Testing & Diagnostics | $2.12B | — | 4.7 | -62.9 | −43.6% | 5/9 | distress |
Figures describe Natera shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.